semaglutide 503b pharmacy US FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs 503B Compounding Pharmacy | Clinical

The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G)

Patients using these medications report noticing an increase in fine lines, wrinkles, loose and sagging skin, and a hollowed-out facial appearance

Platforms like MeAgain centralize shot reminders, injection-site and side-effect logs, nutrition guidance, and dose history so users and clinicians can see the exact sequence that led to a rebound, enabling faster, more targeted responses

Weight loss from GLP-1 therapy typically includes about 40 percent muscle and 60 percent fat

This is a standard rule across compounded prescription medications, not a policy specific to altRx